•Developed
methods of using and administering anti-CD47 agents to treat malignant
pediatric
brain tumors
•Direct
delivery to the cerebrospinal fluid by an implanted continuous delivery device
•Developed
xenograft animal models to test the toxicity together by engrafting with both
normal human neural cells and brain cancer cells
•This
technology provides new methods for treating malignant pediatric brain tumors
and enables more effective preclinical testing of new therapeutics